Logo

Paratek Pharmaceuticals' Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults

Share this
Paratek Pharmaceuticals' Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults

Paratek Pharmaceuticals' Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults

Shots:

  • The approval is based on multiple trial study assessing Nuzyra and resulted in safe- efficacious and well tolerated results
  • Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial drug indicated to treat CABP and  ABSSSI
  • Post marketing approval- Paratek’s plans to evaluate Nuzyra for the treatment of CABP and pediatrics- with its expected marketing in Q1’19

Ref: Paratek Pharmaceuticals | Image: Glassdoor

 

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions